Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Emerging azole antifungals].

Michel Wolff1, Lila Bouadma, Bruno Mourvillier

  • 1Service de Réanimation Médicale et des Maladies Infectieuses, Hôpital Bichat-Claude-Bernard, AP-HP, France. michel.wolff@bch.aphp.fr

Therapie
|September 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delayed intubation and 60-day mortality in severe COVID-19-associated acute respiratory failure in an emulated target trial using the OUTCOMEREA network.

Scientific reports·2026
Same author

Pulse Pressure Variation During Passive Leg Raising to Assess Preload Responsiveness: Influence of Inspiratory Effort During Pressure Support Ventilation.

Critical care medicine·2026
Same author

Performance of the Ventilatory Ratio to Predict Intubation in Patients With COVID-19 Acute Respiratory Distress Syndrome.

Critical care explorations·2026
Same author

Optimized use of the FilmArray Meningitis/Encephalitis panel for early discontinuation of antibiotic therapy.

Microbiology spectrum·2026
Same author

Clinical significance of negative BioFire® pneumonia panel in ICU: Diagnosis, management, and outcomes.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Restrictive vs Liberal Physical Restraint Strategies in Critically Ill Patients: The R2D2-ICU Randomized Clinical Trial.

JAMA·2026

Azole antifungals are crucial for invasive fungal infections in immunocompromised patients. Fluconazole is preferred for candidiasis, while voriconazole and posaconazole target molds like Aspergillus.

Area of Science:

  • Medical Mycology
  • Pharmacology
  • Infectious Diseases

Context:

  • Invasive fungal infections (IFIs) pose a significant threat, particularly to immunocompromised individuals.
  • Azole antifungals are a cornerstone in managing IFIs due to their efficacy and safety profiles.
  • The emergence of resistant fungal strains necessitates a thorough understanding of azole drug characteristics.

Purpose:

  • To review the current role and applications of key azole antifungal agents in treating invasive fungal infections.
  • To highlight the specific indications, strengths, and limitations of fluconazole, itraconazole, voriconazole, and posaconazole.
  • To inform clinical decision-making regarding the optimal use of azoles based on pathogen and patient factors.

Summary:

  • Fluconazole is the primary treatment for most invasive candidiasis, excluding infections by Candida glabrata and Candida krusei.

Related Experiment Videos

  • Itraconazole's utility for invasive mold infections is limited by variable bioavailability, despite activity against Aspergillus species.
  • Voriconazole offers broad-spectrum activity against molds, including Aspergillus, and is a first-line agent for invasive aspergillosis, Fusarium, and Scedosporium infections.
  • Posaconazole, available orally, shows similar in vitro activity and is indicated for refractory aspergillosis, intolerance to other treatments, and potentially for zygomycetes infections.

    • Impact:

    • Optimized selection of azole antifungals can improve patient outcomes and reduce treatment failures in invasive fungal infections.
    • Understanding drug bioavailability and spectrum of activity is critical for effective antifungal stewardship.
    • Further research into novel azole formulations and resistance mechanisms will enhance the management of life-threatening fungal diseases.